Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the
signaling of interleukin (IL)-4 and-13. Several other chronic skin conditions share …

Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of
moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious …

Importance: While dupilumab has emerged as an effective treatment for moderate-to-severe
atopic dermatitis (AD) since its approval in 2017, interleukin-4 and 13 blockade has also …

Introduction Dupilumab represents a breakthrough in the management of atopic dermatitis
(AD), thanks to its powerful T-helper (Th) 2-mediated immunity modulating activity. It can …

Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with
complex immunopathogenesis characterized by a dominant TH2 response. Dupilumab is an …

Background Significant unmet need exists for long-term treatment of moderate to severe
atopic dermatitis (AD). Objective To assess the long-term safety and efficacy of dupilumab in …

Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis
characterized by a T helper 2 (Th2) immune response phenotype and may be associated …

Atopic dermatitis is a chronic inflammatory condition of the skin affecting a large number of
people worldwide. Historically, this condition has been managed by topical corticosteroids …

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The
prevalence of AD is increasing and is currently estimated at 10–20% in adults worldwide. In …

Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and
psychosocial comorbidities decreasing the quality of life for many patients. Dupilumab, a …